Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Neoadjuvant and Adjuvant Fenretinide Compared With Adjuvant Fenretinide Alone in Treating Patients Who Are Undergoing Surgical Resection For Recurrent Glioblastoma Multiforme

23. januar 2013 opdateret af: National Cancer Institute (NCI)

A Phase II Evaluation With Correlative Studies Of Fenretinide (NSC 374551-4HPR) As A Single Agent In The Treatment Of Adult Patients With Recurrent Glioblastoma Multiforme

This randomized phase II trial is studying how well neoadjuvant and adjuvant fenretinide works compared to adjuvant fenretinide alone in treating patients who are undergoing surgical resection for recurrent glioblastoma multiforme. Chemotherapy drugs, such as fenretinide, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy before surgery may shrink the tumor so that it can be removed. Giving chemotherapy after surgery may kill any remaining tumor cells. It is not yet known whether neoadjuvant and adjuvant fenretinide is more effective than adjuvant fenretinide alone

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

PRIMARY OBJECTIVES:

I. Compare the efficacy of neoadjuvant and adjuvant fenretinide vs adjuvant fenretinide alone, in terms of 6-month progression-free survival, in patients with recurrent glioblastoma multiforme undergoing surgical resection II. Correlate the serum and glioma tissue pharmacology of this drug with clinical response in patients treated with these regimens.

III. Determine whether this drug induces apoptosis in glioma tissue in patients treated with these regimens.

IV. Correlate the apoptotic index with tissue and serum concentration and clinical response in patients treated with these regimens.

V. Compare radiological response, overall survival, and unexpected toxicity in patients treated with these regimens.

OUTLINE: This is a randomized study. Patients are randomized to 1 of 2 treatment arms.

Arm I: Patients receive neoadjuvant oral fenretinide twice daily for 1 week and then undergo surgical resection.

Arm II: Patients undergo surgical resection.

Beginning two weeks after surgery, all patients receive adjuvant oral fenretinide twice daily on weeks 1 and 4. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.

PROJECTED ACCRUAL: A total of 21-46 patients (10-23 per treatment arm) will be accrued for this study within 7-46 months.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

42

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Forenede Stater
    • Texas
      • Houston, Texas, Forenede Stater, 77030
        • M D Anderson Cancer Center

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Histologically confirmed glioblastoma multiforme after initial tumor resection

  • Radiologically evident recurrent tumor after prior radiotherapy OR after treatment for no more than 2 prior relapses

    • Enhancing or nonenhancing recurrent disease by MRI
  • No progressive symptoms requiring urgent surgery
  • Performance status - Karnofsky 70-100%
  • More than 8 weeks
  • Absolute granulocyte count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3
  • PT/PTT no greater than upper limit of normal
  • SGPT no greater than 2.5 times normal
  • Alkaline phosphatase no greater than 2.5 times normal
  • Bilirubin less than 1.5 mg/dL
  • BUN no greater than 1.5 times normal
  • Creatinine no greater than 1.5 times normal
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective barrier contraception during and for 2 months after study participation
  • Amylase and lipase normal
  • No active infection
  • No other disease that would obscure toxicity or dangerously alter drug metabolism
  • No other concurrent serious medical illness
  • Not at risk from any study treatment delays
  • Able to swallow fenretinide capsules
  • Recovered from all prior chemotherapy
  • Approximately 2 weeks since prior vincristine
  • Approximately 6 weeks since prior nitrosoureas
  • Approximately 3 weeks since prior procarbazine
  • See Disease Characteristics
  • At least 2 weeks since prior radiotherapy
  • See Disease Characteristics
  • At least 1 week since prior vitamin A
  • At least 1 week since prior isotretinoin (Accutane®)
  • No concurrent vitamin A during and for 2 weeks after study participation
  • No concurrent antioxidants (e.g., ascorbic acid or vitamin E)

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Arm I (fenretinide, surgery)
Patients receive neoadjuvant oral fenretinide twice daily for 1 week and then undergo surgical resection.
Andet: laboratoriebiomarkøranalyse
Korrelative undersøgelser
Andet: farmakologisk undersøgelse
Korrelative undersøgelser
Andre navne:
  • farmakologiske undersøgelser
Procedure: terapeutisk konventionel kirurgi
Gennemgå operation
Medicin: fenretinid
Gives oralt
Andre navne:
  • fenretinimid
  • McN-R-1967
Aktiv komparator: Arm II (surgery)
Patients undergo surgical resection.
Andet: laboratoriebiomarkøranalyse
Korrelative undersøgelser
Andet: farmakologisk undersøgelse
Korrelative undersøgelser
Andre navne:
  • farmakologiske undersøgelser
Procedure: terapeutisk konventionel kirurgi
Gennemgå operation

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Progression-free survival (PFS)
Tidsramme: Up to 6 months
Up to 6 months
Plasma and tissue concentrations of fenretinide and its metabolite, 4-MPR using high-performance liquid chromatography (HPLC) assay
Tidsramme: At baseline, and at 1, 7, 14, and 21 days
At baseline, and at 1, 7, 14, and 21 days
Tumor apoptotic index after fenretinide treatment by immunohistochemistry
Tidsramme: At the time of surgery
At the time of surgery
Correlation between tumor apoptotic index with serum and tissue fenretinide levels
Tidsramme: At the time of surgery
At the time of surgery
Correlation of time to progression with drug levels and apoptotic index
Tidsramme: Up to 2 years
Up to 2 years

Sekundære resultatmål

Resultatmål
Tidsramme
Samlet overlevelse
Tidsramme: Op til 2 år
Op til 2 år
Fenretinide effects on retinol, RBP, retinoid receptor levels and IGF-1
Tidsramme: Up to 21 days (course 1 and 4)
Up to 21 days (course 1 and 4)
Fenretinide activity using magnetic resonance spectroscopy (MRS)
Tidsramme: At the time of surgery
At the time of surgery
Radiological response
Tidsramme: Up to 2 years
Up to 2 years
Unexpected toxicity associated with fenretinide as assessed by CTC version 3.0
Tidsramme: Up to 2 years
Up to 2 years

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

National Cancer Institute (NCI)

Efterforskere

  • Ledende efterforsker: Vinay K. Puduvalli, M.D. Anderson Cancer Center

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. december 2003

Primær færdiggørelse (Faktiske)

1. marts 2005

Studieafslutning

7. december 2022

Datoer for studieregistrering

Først indsendt

9. januar 2004

Først indsendt, der opfyldte QC-kriterier

11. januar 2004

Først opslået (Skøn)

12. januar 2004

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

24. januar 2013

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

23. januar 2013

Sidst verificeret

1. januar 2013

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • NCI-2012-02566
  • ID02-701
  • R21CA097767 (U.S. NIH-bevilling/kontrakt)
  • CDR0000346722 (Registry Identifier: PDQ (Physician Data Query))

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Voksen kæmpecelleglioblastom

Kliniske forsøg med laboratoriebiomarkøranalyse

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Kenya

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

3
Abonner